Dulaglutide (Trulicity)

1. Overview

Dulaglutide (marketed as Trulicity by Eli Lilly and Company) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered as an Fc fusion protein for the treatment of type 2 diabetes mellitus (T2D) [15][17][18]. Unlike peptide-only GLP-1 analogs such as liraglutide or semaglutide, dulaglutide comprises two copies of a modified human GLP-1(7-37) analog covalently linked to the Fc fragment of a modified human immunoglobulin G4 (IgG4) heavy chain via a synthetic 16-amino-acid peptide linker [17]. This fusion protein architecture produces a large molecule (approximately 59.7 kDa as a homodimer) that resists renal clearance and undergoes neonatal Fc receptor (FcRn)-mediated recycling, yielding a plasma half-life of approximately 5 days and enabling once-weekly subcutaneous administration [17][18].

Dulaglutide was approved by the U.S. Food and Drug Administration (FDA) on September 18, 2014, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes [18]. It was the first GLP-1 receptor agonist developed by Eli Lilly and became one of the most widely prescribed therapies in its class worldwide. The clinical development program included eleven AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) phase 3 trials and the landmark REWIND cardiovascular outcomes trial, enrolling over 15,000 participants across the combined programs [12][15].

Type

GLP-1 receptor agonist; Fc fusion protein

Molecular Weight

~59.7 kDa (homodimer)

Structure

Disulfide-bonded homodimer: two GLP-1(7-37) analogs fused to modified human IgG4 Fc via 16-amino-acid linker

Key Modifications

Gly8 (DPP-4 resistance), Glu22 (reduced immunogenicity), Gly36; IgG4 Fc modified to reduce FcR binding

Half-life

~5 days (approximately 120 hours)

Tmax

24-72 hours (median ~48 hours)

Production

Recombinant DNA technology in Chinese hamster ovary (CHO) cells

Route

Subcutaneous injection (once weekly)

FDA Status

Approved September 18, 2014 (type 2 diabetes); CV indication added 2020 (REWIND)

Manufacturer

Eli Lilly and Company

2. Molecular Structure and Design

Dulaglutide is a recombinant fusion protein produced in Chinese hamster ovary (CHO) cells using recombinant DNA technology [17][18]. Its structure consists of two identical polypeptide chains joined by disulfide bonds, forming a homodimer. Each chain contains three functional domains:

GLP-1 analog component. The N-terminal portion of each chain is a modified analog of human GLP-1(7-37) with approximately 90% sequence homology to native GLP-1 [15][17]. Three amino acid substitutions distinguish the analog from the native peptide: glycine replaces alanine at position 8 (Gly8), conferring resistance to cleavage by dipeptidyl peptidase-4 (DPP-4); glutamic acid replaces glycine at position 22 (Glu22), reducing potential immunogenicity; and glycine replaces arginine at position 36 (Gly36). The Gly8 substitution is particularly important, as native GLP-1 has a circulating half-life of only 2-3 minutes due to rapid DPP-4 degradation.

Peptide linker. A 16-amino-acid synthetic linker connects the GLP-1 analog to the Fc fragment, providing sufficient flexibility for the GLP-1 moiety to engage its receptor while maintaining the structural integrity of the Fc domain [17].

Modified IgG4 Fc fragment. The C-terminal portion of each chain consists of the hinge, CH2, and CH3 domains of a human IgG4 heavy chain, modified in the regions responsible for binding high-affinity Fc gamma receptors and for half-antibody formation [17][18]. These modifications minimize potential effector functions (such as antibody-dependent cellular cytotoxicity and complement activation) while preserving FcRn binding, which drives the extended half-life through endosomal recycling.

The overall molecular weight of approximately 59.7 kDa substantially exceeds the renal filtration threshold, reducing glomerular clearance. Combined with FcRn-mediated recycling, this yields a terminal elimination half-life of approximately 5 days (approximately 120 hours), supporting once-weekly dosing [17][18].

3. Mechanism of Action

Dulaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, gastrointestinal epithelium, central nervous system neurons, cardiovascular tissue, and renal cells [15][18].

Glucose-dependent insulin secretion. GLP-1 receptor activation on pancreatic beta cells stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A and Epac2 signaling pathways. This enhances glucose-dependent insulin exocytosis, meaning insulin is released only when blood glucose is elevated, substantially lowering the risk of hypoglycemia compared with sulfonylureas or exogenous insulin [15][18].

Glucagon suppression. Dulaglutide suppresses inappropriate glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, reducing hepatic glucose output and contributing to improved fasting and postprandial glucose control [15].

Gastric emptying delay. Like other GLP-1 receptor agonists, dulaglutide slows gastric emptying, which reduces the rate of glucose appearance in the circulation following meals and contributes to postprandial glucose control and satiety [18]. This effect may attenuate partially with chronic use.

Central appetite regulation. GLP-1 receptors in the hypothalamus (particularly the arcuate nucleus) and hindbrain (nucleus of the solitary tract) mediate reductions in appetite and food intake. While dulaglutide produces modest weight loss in most clinical trials (typically 1.5-3.0 kg), this is less pronounced than observed with semaglutide at comparable clinical doses [14][22].

Cardiovascular and renal pathways. GLP-1 receptor activation has been associated with anti-inflammatory effects on vascular endothelium, natriuresis, reductions in systolic blood pressure, and improvements in lipid profiles [12][23]. The mechanisms underlying cardiovascular and renal benefits observed in REWIND are under active investigation and likely involve both direct receptor-mediated effects and indirect benefits from metabolic improvements.

4. Researched Applications

Type 2 Diabetes Mellitus (Strong Evidence)

The AWARD clinical trial program comprehensively established dulaglutide's efficacy across the type 2 diabetes treatment continuum [1][2][3][4][5][6][15]:

Monotherapy. AWARD-3 demonstrated that dulaglutide monotherapy (1.5 mg and 0.75 mg) was superior to metformin for HbA1c reduction in 807 treatment-naive patients [3].

Add-on to oral agents. AWARD-5 (n=1,098) showed superiority of both dulaglutide doses over sitagliptin 100 mg when added to metformin, with HbA1c reductions of 1.10% (1.5 mg) and 0.87% (0.75 mg) versus 0.39% (sitagliptin) at 52 weeks [5]. AWARD-1 (n=978) demonstrated superiority over exenatide twice daily [1]. AWARD-8 (n=299) showed significant benefit when added to glimepiride [16]. AWARD-10 (n=424) demonstrated complementary efficacy when added to SGLT2 inhibitors [9].

Comparison with insulin. In AWARD-2 (n=810), dulaglutide 1.5 mg was superior to titrated insulin glargine in patients on metformin plus glimepiride over 78 weeks [2]. AWARD-4 (n=884) showed that dulaglutide plus prandial insulin lispro was superior to basal-bolus insulin for HbA1c reduction [4]. AWARD-9 (n=300) demonstrated benefit as add-on to titrated basal insulin [8].

Head-to-head with liraglutide. AWARD-6 (n=599) established non-inferiority of dulaglutide 1.5 mg once weekly to liraglutide 1.8 mg once daily for HbA1c reduction (-1.42% vs -1.36%), though liraglutide produced modestly greater weight loss [6].

Higher doses. AWARD-11 (n=1,842) evaluated expanded doses of 3.0 mg and 4.5 mg versus 1.5 mg, demonstrating incremental HbA1c reductions (-1.64% and -1.77% vs -1.54%) and weight loss at 36 weeks [10].

Pediatric use. AWARD-PEDS (n=154) was the first trial of a GLP-1 receptor agonist in youth with type 2 diabetes, showing that dulaglutide 1.5 mg reduced HbA1c by 0.9 percentage points while placebo increased it by 0.6 points, published in the New England Journal of Medicine in 2022 [11].

Cardiovascular Outcomes (Strong Evidence)

The REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial was a landmark cardiovascular outcomes trial that enrolled 9,901 adults aged 50 years or older with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors [12]. Uniquely among GLP-1 receptor agonist CVOTs, 69% of REWIND participants had cardiovascular risk factors only, without established cardiovascular disease, making it the first trial to assess cardiovascular benefit in a predominantly primary-prevention population.

Over a median follow-up of 5.4 years (the longest of any GLP-1 RA CVOT at the time), dulaglutide 1.5 mg once weekly reduced the primary composite endpoint of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) by 12% compared with placebo (HR 0.88; 95% CI 0.79-0.99; p=0.026) [12]. The reduction was driven primarily by a significant decrease in nonfatal stroke (HR 0.76; 95% CI 0.61-0.95). Post hoc analysis demonstrated that the benefit extended to total cardiovascular or fatal events, with consistent results across key subgroups including those with and without prior cardiovascular events [24].

Renal Outcomes (Strong Evidence)

A prespecified secondary analysis of the REWIND trial examined the composite renal endpoint of new-onset macroalbuminuria (UACR greater than 33.9 mg/mmol), sustained 30% or greater decline in eGFR from baseline, or initiation of chronic renal replacement therapy [13]. During the 5.4-year median follow-up, dulaglutide reduced this composite renal outcome by 15% (HR 0.85; 95% CI 0.77-0.93; p=0.0004). The most prominent component was prevention of new macroalbuminuria (HR 0.77; 95% CI 0.68-0.87; p value less than 0.0001) [13].

These findings were reinforced by AWARD-7 (n=577), which specifically enrolled patients with moderate-to-severe CKD (stages 3-4) and demonstrated that dulaglutide preserved eGFR more effectively than insulin glargine over 52 weeks, with comparable glycemic control [7]. Further post hoc analysis of REWIND confirmed durable kidney function benefits over the extended follow-up period [19].

Comparison with Other GLP-1 Receptor Agonists

The SUSTAIN-7 trial (n=1,201), conducted by Novo Nordisk, directly compared semaglutide and dulaglutide head-to-head [14]. Semaglutide demonstrated statistically superior HbA1c reductions and weight loss at both dose comparisons: semaglutide 0.5 mg reduced HbA1c by 1.5% versus 1.1% with dulaglutide 0.75 mg, and semaglutide 1.0 mg reduced HbA1c by 1.8% versus 1.4% with dulaglutide 1.5 mg. Body weight reductions were approximately double with semaglutide (4.6 kg vs 2.3 kg at low doses; 6.5 kg vs 3.0 kg at high doses) [14]. Safety profiles were broadly similar between the two agents.

Within the GLP-1 receptor agonist class, the key comparative points are:

• vs. semaglutide: Semaglutide provides greater HbA1c reduction and substantially greater weight loss. The SUSTAIN-6 trial showed semaglutide reduced MACE by 26% (HR 0.74), and the SELECT trial demonstrated 20% MACE reduction in patients without diabetes [14][20]. However, REWIND enrolled a broader population with longer follow-up.
• vs. liraglutide: AWARD-6 demonstrated non-inferiority for glycemic control with the convenience advantage of weekly vs daily dosing [6]. The LEADER trial showed liraglutide reduced MACE by 13% (HR 0.87) in 9,340 patients [21], numerically similar to the 12% reduction in REWIND.
• vs. exenatide: AWARD-1 demonstrated superiority of dulaglutide over exenatide twice daily for HbA1c reduction [1].

5. Pharmacokinetics

Dulaglutide exhibits a pharmacokinetic profile uniquely shaped by its Fc fusion protein architecture, which exploits both size-based renal filtration avoidance and FcRn-mediated endosomal recycling to achieve once-weekly dosing [17][18].

Absorption. Following subcutaneous injection, dulaglutide is absorbed slowly from the injection site, reaching peak plasma concentrations (Cmax) at a median Tmax of approximately 48 hours (range 24-72 hours). The absolute subcutaneous bioavailability ranges from 47% to 65% depending on injection site, with abdominal and thigh sites producing comparable exposure. The slow absorption from the subcutaneous depot contributes to the sustained, flat pharmacokinetic profile that minimizes peak-to-trough fluctuations over the weekly dosing interval [17][18].

Distribution. The apparent volume of distribution following subcutaneous administration is approximately 19.2 L, consistent with predominantly intravascular and interstitial distribution expected for a large 59.7 kDa protein. Dulaglutide does not extensively distribute to tissues beyond the extracellular space. The Fc domain mediates binding to FcRn in endothelial and hematopoietic cells, where the protein is internalized by pinocytosis, protected from lysosomal degradation through pH-dependent FcRn binding in acidic endosomes (pH 6.0), and recycled back to the cell surface for release at physiological pH (7.4) [17].

Metabolism and elimination. Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolic pathways. The Fc modifications that reduce Fc gamma receptor binding prevent significant immune-mediated clearance. The terminal elimination half-life is approximately 5 days (approximately 120 hours), reaching steady-state concentrations by 2-4 weeks of once-weekly dosing. Steady-state Cmax is approximately 114 ng/mL for the 1.5 mg dose. Dulaglutide is not primarily cleared by the kidneys or liver; no dose adjustment is required for patients with renal impairment (including eGFR as low as 15 mL/min/1.73 m2) or mild-to-moderate hepatic impairment [17][18].

Special populations. Population pharmacokinetic analyses across the AWARD program demonstrated that age (18-87 years), sex, race/ethnicity, body weight (up to 199 kg), and renal function do not require dose adjustment. Dulaglutide exposure decreases modestly with increasing body weight, but this did not translate into clinically meaningful differences in efficacy across BMI categories in the AWARD trials [15][18]. In the pediatric AWARD-PEDS population (ages 10-17), pharmacokinetics were consistent with adult data at the same doses [11].

Drug interactions. As a large protein, dulaglutide does not interact with cytochrome P450 enzymes and has no known pharmacokinetic drug-drug interactions. However, its effect on gastric emptying delay may affect the rate (but not extent) of absorption of concomitant oral medications. A specific pharmacokinetic study with acetaminophen showed delayed Tmax but unchanged total exposure (AUC) [18].

6. Dose-Response Relationships

The AWARD program and dose-ranging studies provide comprehensive dose-response data across four approved dose strengths (0.75, 1.5, 3.0, and 4.5 mg) [10][15].

HbA1c dose-response. Across the AWARD program, a clear and consistent dose-response relationship was observed for glycemic control. In AWARD-11 (n=1,842), the definitive dose-response trial, HbA1c reductions at 36 weeks were: 1.5 mg (-1.54%), 3.0 mg (-1.64%), and 4.5 mg (-1.77%), with statistically significant superiority of 4.5 mg over 1.5 mg (difference -0.24%; 95% CI -0.36 to -0.11; p value less than 0.001) [10]. The dose-response curve shows a diminishing incremental return: moving from 0.75 to 1.5 mg typically provides a 0.2-0.3% additional HbA1c reduction, while moving from 1.5 to 4.5 mg provides approximately 0.2% further reduction.

Weight loss dose-response. Weight loss in AWARD-11 was dose-dependent: 1.5 mg (-3.1 kg), 3.0 mg (-4.0 kg), and 4.5 mg (-4.7 kg) at 36 weeks [10]. The higher doses produced approximately 50% greater weight loss than 1.5 mg, though the absolute magnitude remains modest compared to semaglutide and tirzepatide at their highest doses.

Target attainment. The proportion of patients achieving HbA1c targets showed a dose-dependent pattern: at the target of 7.0% or below, achievement rates in AWARD-11 were approximately 57% (1.5 mg), 64% (3.0 mg), and 68% (4.5 mg). At the more stringent target of 6.5% or below, rates were 37%, 43%, and 50% respectively [10].

Gastrointestinal tolerability dose-response. Gastrointestinal adverse events increase modestly with dose, though the dose-response curve for side effects is flatter than for efficacy. Nausea rates in AWARD-11 were approximately 12% (1.5 mg), 16% (3.0 mg), and 18% (4.5 mg). The favorable efficacy-to-tolerability ratio supports dose escalation in patients requiring additional glycemic control [10].

Cardiovascular dose-response. Only the 1.5 mg dose has been studied in a cardiovascular outcomes trial (REWIND), so the cardiovascular dose-response remains unknown. Whether higher doses (3.0 or 4.5 mg) would provide greater cardiovascular benefit is an unanswered question [12].

7. Comparative Effectiveness

Dulaglutide vs Semaglutide

The SUSTAIN-7 trial (n=1,201) provides the most rigorous head-to-head evidence comparing these two once-weekly GLP-1 receptor agonists [14][22]. At both dose comparisons studied:

• Low dose comparison (dulaglutide 0.75 mg vs semaglutide 0.5 mg): Semaglutide reduced HbA1c by 1.5% versus 1.1% with dulaglutide (estimated treatment difference -0.40%; p value less than 0.0001). Weight loss was 4.6 kg with semaglutide versus 2.3 kg with dulaglutide (p value less than 0.0001) [14].
• High dose comparison (dulaglutide 1.5 mg vs semaglutide 1.0 mg): Semaglutide reduced HbA1c by 1.8% versus 1.4% with dulaglutide (difference -0.41%; p value less than 0.0001). Weight loss was 6.5 kg versus 3.0 kg (p value less than 0.0001) [14].

Semaglutide thus demonstrates approximately double the weight loss and 0.4% greater HbA1c reduction at comparable clinical doses. However, dulaglutide offers advantages in not requiring dose titration (unlike semaglutide's mandatory 4-week escalation steps) and has demonstrated cardiovascular benefit in a predominantly primary-prevention population (REWIND), whereas SUSTAIN-6 enrolled a higher-risk secondary-prevention cohort [12][20].

For cardiovascular outcomes: REWIND showed 12% MACE reduction (HR 0.88) with 5.4-year follow-up in a 69% primary-prevention population [12]. SUSTAIN-6 showed 26% MACE reduction (HR 0.74) over 2.1 years in a predominantly secondary-prevention population [20]. The SELECT trial demonstrated 20% MACE reduction with semaglutide 2.4 mg in overweight/obese patients without diabetes. Direct CVOT comparisons are confounded by differences in population, follow-up duration, and dose selection.

Dulaglutide vs Liraglutide

AWARD-6 (n=599) established non-inferiority of dulaglutide 1.5 mg once weekly to liraglutide 1.8 mg once daily for HbA1c reduction (-1.42% vs -1.36%; difference -0.06%; 95% CI -0.19 to 0.07) [6]. Liraglutide produced modestly greater weight loss (-3.61 kg vs -2.90 kg; p=0.011). The principal advantage of dulaglutide is the convenience of once-weekly versus once-daily dosing. In the cardiovascular space, LEADER showed liraglutide reduced MACE by 13% (HR 0.87) in 9,340 high-risk patients [21], numerically similar to the 12% reduction in REWIND, though REWIND had longer follow-up and a lower-risk population.

Dulaglutide vs Tirzepatide

No direct head-to-head trial has compared dulaglutide with tirzepatide. However, cross-trial comparisons suggest substantially greater efficacy with tirzepatide (a dual GIP/GLP-1 receptor agonist). The SURPASS program demonstrated HbA1c reductions of 1.9-2.6% and weight loss of 7-13 kg with tirzepatide, exceeding the maximal effects observed with dulaglutide 4.5 mg (HbA1c -1.77%, weight -4.7 kg in AWARD-11) [10][22]. Tirzepatide's dual incretin mechanism provides additional glucose-dependent insulinotropic polypeptide (GIP) receptor agonism that dulaglutide lacks.

Position in the GLP-1 Receptor Agonist Landscape

Dulaglutide remains a widely prescribed GLP-1 receptor agonist with a strong clinical evidence base. Its key competitive advantages include the most extensive primary-prevention cardiovascular data (REWIND), the largest pediatric dataset (AWARD-PEDS), no requirement for dose titration at standard doses, a robust renal outcomes dataset, and broad clinical experience across diverse patient populations. Its main limitation relative to newer agents is the more modest weight loss, which has become increasingly important as obesity management has emerged as a central treatment goal [22][23].

Evolving Market Position (2025-2026 Update)

With Trulicity's core patents approaching expiry around 2027, the competitive landscape for dulaglutide is shifting. Biosimilar candidates are in development, and Eli Lilly's own pipeline has advanced considerably with tirzepatide (Mounjaro/Zepbound) and the oral non-peptide GLP-1 RA orforglipron. In 2025, the ACHIEVE-3 trial demonstrated that oral orforglipron 36 mg achieved HbA1c reductions of -2.2% and weight loss of 9.2% -- substantially exceeding the efficacy typically seen with dulaglutide 1.5 mg. As biosimilars enter the market, dulaglutide may increasingly serve as a cost-effective GLP-1 RA option in healthcare systems where newer agents remain inaccessible due to cost, while patients who can access newer therapies may transition to tirzepatide, semaglutide, or orforglipron for greater metabolic benefit.

8. Enhanced Safety Profile

The safety profile of dulaglutide is supported by one of the largest safety databases among GLP-1 receptor agonists, encompassing over 6,000 AWARD participants and 9,901 REWIND participants over a median 5.4 years [12][15].

Long-term cardiovascular safety. REWIND provided the longest placebo-controlled safety follow-up of any GLP-1 RA CVOT (median 5.4 years), with no increase in heart failure hospitalizations, cardiac arrhythmias, or cardiovascular mortality. The modest increase in resting heart rate (2-4 beats per minute) remained stable over the treatment period and was not associated with adverse cardiovascular outcomes [12][24].

Thyroid safety in humans. Despite the rodent C-cell tumor signal (reflected in the FDA boxed warning), no increase in medullary thyroid carcinoma or C-cell hyperplasia has been identified in post-marketing surveillance spanning over a decade of clinical use. Calcitonin levels remained stable in clinical trials, and population-based studies have not detected an increased thyroid cancer risk with GLP-1 receptor agonists [15][18].

Pancreatitis and pancreatic cancer. Acute pancreatitis occurred at rates of 1-3 per 1,000 patient-years in the AWARD program, similar to rates observed with comparators. The REWIND trial, with its 5.4-year follow-up, found no increased risk of pancreatitis or pancreatic cancer with dulaglutide [12].

Gallbladder events. Cholelithiasis and cholecystitis have been reported at modestly increased rates with GLP-1 receptor agonists as a class, likely related to rapid weight loss and altered gallbladder motility. In the AWARD program, gallbladder events were uncommon (approximately 1-2%) [15].

Immunogenicity. Treatment-emergent anti-dulaglutide antibodies developed in approximately 1-2% of patients, with neutralizing antibodies in less than 1%. The low immunogenicity rate likely reflects the humanized IgG4 Fc design. Anti-drug antibodies did not correlate with reduced efficacy, increased adverse events, or injection site reactions [15].

Renal safety. Dulaglutide has shown a renal-protective profile. In REWIND, the composite renal endpoint was reduced by 15% (HR 0.85), and AWARD-7 demonstrated preserved eGFR in CKD stages 3-4 [7][13][19]. No dose adjustment is required at any level of renal impairment, and acute kidney injury has not been identified as a safety signal at higher rates than background [18].

Pregnancy and lactation. Dulaglutide is not recommended during pregnancy or lactation due to insufficient human data. Animal studies showed reduced fetal growth at supratherapeutic doses. Dulaglutide should be discontinued at least 2 months before a planned pregnancy given its extended half-life [18].

9. Clinical Evidence Summary

10. Dosing in Research

In clinical trials, dulaglutide was administered as a once-weekly subcutaneous injection using a single-dose pen device with a pre-attached, hidden needle designed to simplify self-injection [15][18].

Standard dosing (AWARD 1-10). The recommended starting dose was 0.75 mg once weekly, which could be increased to 1.5 mg once weekly for additional glycemic control. No dose-titration period was required, unlike semaglutide, which necessitates gradual escalation [15].

Higher doses (AWARD-11). Expanded doses of 3.0 mg and 4.5 mg were studied in patients already on 1.5 mg who required additional glycemic control, with escalation from 1.5 mg to 3.0 mg and then to 4.5 mg at 4-week intervals [10].

REWIND. All participants received a fixed dose of 1.5 mg once weekly, with no dose titration, for a median of 5.4 years [12].

Pediatric (AWARD-PEDS). Youth aged 10-17 years received 0.75 mg or 1.5 mg once weekly [11].

11. Safety and Side Effects

The safety profile of dulaglutide has been characterized across the AWARD program (over 6,000 participants) and the REWIND trial (9,901 participants over a median 5.4 years), representing one of the most extensive safety databases among GLP-1 receptor agonists [12][15].

Gastrointestinal effects. The most common adverse events are gastrointestinal in nature, consistent with the GLP-1 receptor agonist class. In AWARD trials, nausea occurred in approximately 12-21% of dulaglutide-treated patients (typically at the 1.5 mg dose), diarrhea in approximately 9-13%, vomiting in approximately 6-12%, and abdominal pain in approximately 6-9% [1][5][15]. These effects are generally mild to moderate in severity, most frequent during the first 2-4 weeks of treatment, and diminish with continued use. Gastrointestinal adverse events led to treatment discontinuation in approximately 2-6% of dulaglutide-treated participants across trials. At the higher doses studied in AWARD-11 (3.0 mg and 4.5 mg), gastrointestinal side effects were modestly more frequent [10].

Thyroid C-cell tumors (boxed warning). Dulaglutide carries an FDA boxed warning regarding the risk of thyroid C-cell tumors [18]. In rodent carcinogenicity studies, dulaglutide caused a dose-related and treatment-duration-dependent increase in thyroid C-cell tumors (adenomas and carcinomas). This effect is believed to be mediated by GLP-1 receptor expression on rodent thyroid C-cells, which is substantially lower or absent in human thyroid C-cells. It remains unknown whether dulaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Dulaglutide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis. Acute pancreatitis has been reported at low rates in clinical trials with dulaglutide. Patients should be monitored for signs and symptoms, and dulaglutide should be discontinued if pancreatitis is suspected [15][18].

Hypoglycemia. Hypoglycemia risk is low with dulaglutide monotherapy or when combined with metformin, owing to its glucose-dependent mechanism of action. However, the risk increases when dulaglutide is combined with sulfonylureas or insulin. In AWARD-8 (dulaglutide plus glimepiride), total hypoglycemia was significantly higher with dulaglutide than placebo (2.37 vs 0.07 events per participant per year), though no severe hypoglycemia was reported [16].

Injection site reactions. Injection site reactions were generally mild and reported in approximately 1-2% of patients. The single-use pen design with a pre-attached, hidden needle was associated with high patient acceptance scores in the AWARD program [15].

Heart rate. Small increases in resting heart rate (typically 2-4 beats per minute) have been observed with dulaglutide, consistent with the GLP-1 receptor agonist class [12][15].

Immunogenicity. Treatment-emergent anti-drug antibodies were detected in approximately 1-2% of dulaglutide-treated patients in clinical trials. The incidence of neutralizing antibodies was very low and did not appear to affect efficacy or safety [15].

Long-term safety. The REWIND trial provided reassuring long-term safety data over a median 5.4-year follow-up period, with no new safety signals emerging beyond the known class effects [12].

12. Regulatory Status

United States (FDA). Trulicity (dulaglutide) was approved on September 18, 2014, as the first once-weekly GLP-1 receptor agonist from Eli Lilly, at doses of 0.75 mg and 1.5 mg for the treatment of type 2 diabetes in adults [18]. In February 2020, following the REWIND results, the FDA approved a supplemental indication for dulaglutide to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [12]. In June 2022, dulaglutide received approval for use in pediatric patients aged 10 years and older with type 2 diabetes based on the AWARD-PEDS trial [11]. In September 2020, the higher dose strengths of 3.0 mg and 4.5 mg were approved based on AWARD-11 data [10].

European Union (EMA). Trulicity received marketing authorization in November 2014 for the treatment of type 2 diabetes in adults.

Other jurisdictions. Dulaglutide has been approved in Japan, Canada, Australia, and numerous additional countries worldwide.

Patent Expiry and Biosimilar Landscape

Trulicity's core composition patents and regulatory data exclusivity are projected to lapse in approximately 2027, approaching a significant patent cliff for Eli Lilly. As of early 2026, no biosimilar version of dulaglutide has been approved, though active development is underway with at least one biosimilar candidate (LY05008) demonstrating comparable efficacy and safety in Phase 1/3 clinical trials. Given dulaglutide's position as one of the most widely prescribed GLP-1 RAs globally, the entry of biosimilars is expected to significantly improve access and affordability, particularly in healthcare systems where access to newer agents (tirzepatide, semaglutide) remains constrained by cost. Unlike small-molecule generics, biosimilars typically cause gradual list-price reductions but more pronounced net revenue declines due to competitive formulary management.

13. Related Peptides

See also: Semaglutide, Liraglutide, Exenatide, Tirzepatide

14. References

1. [1] Wysham C, Blevins T, Arakaki R, et al. (2014). Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care. DOI PubMed
2. [2] Giorgino F, Benroubi M, Sun JH, et al. (2015). Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. DOI PubMed
3. [3] Umpierrez G, Tofe Povedano S, Perez Manghi F, et al. (2014). Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care. DOI PubMed
4. [4] Blonde L, Jendle J, Gross J, et al. (2015). Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. The Lancet. DOI PubMed
5. [5] Nauck M, Weinstock RS, Umpierrez GE, et al. (2014). Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care. DOI PubMed
6. [6] Dungan KM, Povedano ST, Forber T, et al. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. DOI PubMed
7. [7] Tuttle KR, Lakshmanan MC, Rayner B, et al. (2018). Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes & Endocrinology. DOI PubMed
8. [8] Pozzilli P, Norwood P, Jodar E, et al. (2017). Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9). Diabetes, Obesity and Metabolism. DOI PubMed
9. [9] Ludvik B, Frias JP, Tinahones FJ, et al. (2018). Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes & Endocrinology. DOI PubMed
10. [10] Frias JP, Bonora E, Nevarez Ruiz L, et al. (2021). Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. DOI PubMed
11. [11] Araki E, Mysnikova J, Engel SS, et al. (2022). Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. New England Journal of Medicine. DOI PubMed
12. [12] Gerstein HC, Colhoun HM, Dagenais GR, et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. DOI PubMed
13. [13] Gerstein HC, Colhoun HM, Dagenais GR, et al. (2019). Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet. DOI PubMed
14. [14] Pratley RE, Aroda VR, Lingvay I, et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. DOI PubMed
15. [15] Jendle J, Grunberger G, Blevins T, et al. (2016). Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes/Metabolism Research and Reviews. DOI PubMed
16. [16] Grunberger G, Chang A, Garcia Soria G, et al. (2016). A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes, Obesity and Metabolism. DOI PubMed
17. [17] Barrington P, Chien JY, Tibaldi F, et al. (2011). LY2189265, a long-acting glucagon-like peptide-1 analogue fused to an Fc antibody fragment, for the potential treatment of type 2 diabetes. Current Opinion in Investigational Drugs. PubMed
18. [18] Smith LL, Mosley JF, Parke C, et al. (2016). Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Receptor Agonist. P&T. PubMed
19. [19] Gerstein HC, Colhoun HM, Dagenais GR, et al. (2023). Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: A REWIND Post Hoc Analysis. Diabetes Care. DOI PubMed
20. [20] Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. DOI PubMed
21. [21] Marso SP, Daniels GH, Poulter NR, et al. (2016). Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. DOI PubMed
22. [22] Trujillo JM, Nuffer W, Smith BA. (2021). GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Therapeutic Advances in Endocrinology and Metabolism. DOI PubMed
23. [23] Sheahan KH, Wahlberg EA, Gilbert MP. (2020). An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgraduate Medical Journal. DOI PubMed
24. [24] Gerstein HC, Sattar N, Engel S, et al. (2020). Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trial: a post hoc analysis. Cardiovascular Diabetology. DOI PubMed